|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
ES2539411T3
(es)
|
1999-08-23 |
2015-06-30 |
Dana-Farber Cancer Institute, Inc. |
PD-1, receptor para la B7-4 y su utilización
|
|
ES2367430T3
(es)
|
2002-12-23 |
2011-11-03 |
Wyeth Llc |
Anticuerpos contra pd-1 y sus usos.
|
|
EP3530736A3
(en)
|
2005-05-09 |
2019-11-06 |
ONO Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
|
KR101704734B1
(ko)
|
2005-07-01 |
2017-02-09 |
이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
|
|
WO2008114733A1
(ja)
|
2007-03-16 |
2008-09-25 |
Kyowa Hakko Kirin Co., Ltd. |
抗Claudin-4抗体
|
|
PT2170959E
(pt)
|
2007-06-18 |
2014-01-07 |
Merck Sharp & Dohme |
Anticorpos para o receptor humano de morte programada pd-1
|
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
|
WO2010098788A2
(en)
|
2008-08-25 |
2010-09-02 |
Amplimmune, Inc. |
Pd-i antagonists and methods for treating infectious disease
|
|
PL2346994T3
(pl)
|
2008-09-30 |
2022-04-19 |
Ablexis, Llc |
Myszy knock-in do wytwarzania chimerycznych przeciwciał
|
|
MX356367B
(es)
|
2008-12-09 |
2018-05-25 |
Genentech Inc |
Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
|
|
EP3279215B1
(en)
|
2009-11-24 |
2020-02-12 |
MedImmune Limited |
Targeted binding agents against b7-h1
|
|
EP2504028A4
(en)
|
2009-11-24 |
2014-04-09 |
Amplimmune Inc |
SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
|
|
CA2833636A1
(en)
|
2011-04-20 |
2012-10-26 |
Amplimmune, Inc. |
Antibodies and other molecules that bind b7-h1 and pd-1
|
|
EP2707723B1
(en)
|
2011-05-12 |
2016-02-10 |
Genentech, Inc. |
Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
|
|
BR112014012819B1
(pt)
|
2011-11-28 |
2022-08-16 |
Merck Patent Gmbh |
Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
|
|
BR112015007184A2
(pt)
|
2012-10-02 |
2017-08-08 |
Bristol Myers Squibb Co |
combinação de anticorpos anti-kir e anticorpos anti-pd-1 para tratar câncer
|
|
MX380176B
(es)
*
|
2014-04-07 |
2025-03-12 |
Chugai Pharmaceutical Co Ltd |
Molecula ligada a antigeno inmunoactivada.
|
|
EP3064507A1
(en)
*
|
2015-03-06 |
2016-09-07 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
|
|
RU2727165C2
(ru)
|
2015-05-04 |
2020-07-21 |
ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ |
Слитый полипептид с противораковой активностью
|
|
BR112018071612A2
(pt)
*
|
2016-04-22 |
2019-02-19 |
Alligator Bioscience Ab |
polipeptídeos biespecíficos inovadores contra cd137
|
|
PH12022552323A1
(en)
*
|
2020-03-31 |
2023-12-04 |
Chugai Pharmaceutical Co Ltd |
Claudin-6 targeting multispecific antigen-binding molecules and uses thereof
|
|
CN116133684B
(zh)
|
2020-05-27 |
2025-07-18 |
阿里亚利斯治疗公司 |
抗人nr1抗体衍生物
|
|
IL307744A
(en)
*
|
2021-04-22 |
2023-12-01 |
Astellas Pharma Inc |
Anti-CLDN4/anti-CD137 bispecific antibody
|